To determine whether there was some adaptation in vivo, such as exposure to host-derived factors in the tumor microenvironment that rendered tumor cells susceptible to growth-promoting effects of glucocorticoids, CRISPR/Cas9 targeting was used to generate Nr3c1-deficient B16 cells (Supplemental Figure 2E). Here, NR3C1 is linked to neoplasm.